📣 Award-winning collaboration ensures the voice of patients plays a prominent role in the way cancer therapies are assessed. The Setting International Standards of Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials (known as SISAQOL-IMI) consortium have received the prestigious SPAIG (the Statistical Partnerships Among Academe, Industry, and Government) Award for 2024 from the American Statistical Association for their work to improve standards in the design and analysis of cancer trials with patient reported outcomes. The international multidisciplinary consortium, which includes experts from the MHRA, is developing a consensus-based set of best practice recommendations for the design, analysis, presentation, and interpretation of patient reported outcome (PRO) data. The award honours years of intensive work and successful cooperation between the stakeholder groups which include patient representatives. This work will help to better communicate patient reported outcome results between clinicians and patients for the purposes of shared decision making. The recommendations are also likely to be applicable to other therapeutic areas beyond oncology. To learn more about SISAQOL-IMI, visit ➡️ https://bit.ly/4fI0TYZ
Medicines and Healthcare products Regulatory Agency’s Post
More Relevant Posts
-
🚀 Pleased to share our recent publication, which I co-authored with my Boston Consulting Group (BCG) colleagues Hugo Larose, PhD, Myrto Lee and Jens Grueger, alongside a group of eminent experts in the fields of Oncology and market access. We are challenging traditional ways of assessing the value of cancer therapies, to improve patient access to innovative therapies. 🧬🔍 Our work proposes new principles for evaluating oncology treatments. These include prioritizing patient-reported outcomes, considering broader economic and societal impacts, and integrating more relevant endpoints beyond overall survival. 🌟 This research is a step towards a future in which evaluations of cancer therapy value progress in tandem with rapid advancements in research, thereby enhancing development and accessibility of life-saving therapies. Dive into our findings and join the conversation on reshaping cancer care evaluation! https://lnkd.in/emzSX3HQ #CancerResearch #Innovation #Healthcare #Oncology #bcg #marketaccess
-
Today the Journal of the National Comprehensive Cancer Network® (NCCN®) published “Life Years Gained from the FDA Accelerated Approval Program in Oncology: A Portfolio Model.” Our analysis is the first to estimate patient life years gained among cancer patients because the #FDA #AcceleratedApproval Program facilitated access to treatment sooner than traditional approval, demonstrating the impact of policies on patients’ lives. Key findings: - From 2006 to 2022, the analysis estimated that the program added about 263,000 life years across 69 products for which overall survival data was available, for approximately 911,000 cancer patients. If this timeline was extended to 2026, it would increase to 382,000 years. - In a subgroup analysis, we estimated that those with an orphan designation had a gain of 145,413 life years in 264,061 patients, a 16.5% gain over standard of care. This analysis supports our position at Johnson & Johnson Innovative Medicine that policies -- and any proposed changes -- should be evidence-based and patient-centric. Thank you to co-authors Agnes Benedict, Gabor Szabo, Kinga Marczell, and Bridget Doherty, MPH for a terrific partnership! Please read the analysis here: https://lnkd.in/edUEcS5j
-
Trend Opinion at ASCO 2024: Leading the Way in Oncology Market Research! 🌟 We are excited to share that several esteemed doctors from our panel at Trend Opinion had the privilege of attending the 2024 ASCO (American Society of Clinical Oncology) Annual Meeting in Chicago! 🎉 This year's ASCO conference brought together over 40,000 oncology professionals from around the globe, showcasing the latest advancements in cancer research, treatment protocols, and patient care innovations. Our panel of doctors immersed themselves in this rich environment of knowledge, attending sessions on: 🔬 Cutting-Edge Clinical Trials: Exploring the newest findings in cancer treatment and their potential impacts on patient outcomes. 💉 Innovative Treatment Protocols: Understanding breakthroughs in immunotherapy, targeted therapies, and personalized medicine. 📊 Emerging Trends in Oncology: Identifying key trends and future directions in cancer research and treatment. The insights gained from ASCO 2024 are invaluable to our mission at Trend Opinion. By staying at the forefront of oncology advancements, we ensure that our market research is not only current but also deeply informed by the latest scientific discoveries. This commitment allows us to provide our clients with accurate, actionable insights that drive strategic decision-making in the ever-evolving field of oncology. We are proud to support the oncology community and contribute to the fight against cancer through our comprehensive market research and expert analysis. Stay tuned as we integrate these learnings into our upcoming reports and projects. Together, we're advancing cancer care and making a difference. 💪 #ASCO2024 #OncologyResearch #CancerCare #MarketResearch #HealthcareInnovation #TrendOpinion
-
-
On this #WorldCancerResearchDay, Asia Society's Cure4Cancer in collaboration with the Bloomberg New Economy International Cancer Coalition, Memorial Sloan Kettering Cancer Center, and McKinsey Cancer Center, unveils a pivotal new study that highlights a stark reality: fewer than 5% of eligible patients globally are participating in oncology clinical trials, despite an astounding $80 billion in biopharmaceutical R&D investment. The report sheds light on key barriers—across patient, clinician, and regulatory levels—that are preventing broader participation in trials, which are critical to advancing cancer treatments and care. Cure4Cancer is a global movement launched in 2018 by the Asia Society, Memorial Sloan Kettering Cancer Center (MSK), and the Chinese Thoracic Oncology Group (CTONG), joined by Bloomberg New Economy Forum, Forbes China, Thoracic Oncology Group of Australasia (TOGA), Hospital Sirio-Libanes, and KRAS Kickers and others over the years, with a mission to accelerate the development of cancer cures and prevention through increased public awareness, international cooperation, and regulatory harmonization on patient-centric international clinical trials. Read the full study and learn more about how these strategies can shape the future of cancer care here: https://lnkd.in/es3Cjgnr #Cure4Cancer #CancerResearch #oncology #clinicaltrials
Advancing Global Health Equity in Oncology Clinical Trial Access
aacrjournals.org
-
"Participation in #cancer #treatment #clinicaltrials was higher than historical estimates, according to a national sample of data from the Commission on Cancer. From 2013 to 2017, the overall estimated participation rate in cancer treatment trials was 7.1%, which was higher than historical estimates of less than 5%, reported Joseph M. Unger, PhD, of the Fred Hutch Cancer Center in Seattle, and colleagues. Cancer treatment trial participation estimates have been based on studies of enrollment in National Cancer Institute (NCI)-sponsored cooperative group trials, with estimates ranging from 1.5% to 4%, the authors noted in the Journal of Clinical Oncology." The researchers point out that these estimates do not account for trials sponsored by #pharmaceutical companies, which boosts the participation rate to 7.1%. Article: 'More patients participate in cancer treatment trials than previously estimated' https://lnkd.in/ddREP3fq via MedPage Today #clinicalresearch #health #oncology
More Patients Participate in Cancer Treatment Trials Than Previously Estimated
medpagetoday.com
-
At this year’s American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, the team at Johnson & Johnson Innovative Medicine will be sharing data across our #BladderCancer portfolio, including real-world data on our innovative targeted releasing systems. These findings are a shining testament to the potential promise of novel drug delivery and precision medicine in the treatment of bladder cancer. They indicate how advanced diagnostics are enabling us to identify molecular drivers of disease and develop the next wave of targeted therapeutics — inching us closer to our goal of ensuring patients have the option to receive personalized healthcare interventions that they’re most likely to respond to as early as possible in their disease. With our patient-centric approach, we will continue to rigorously pursue bladder-preserving therapies in earlier-stage disease and work to improve the quality of life of those living with bladder cancer. Learn more about our progress in bladder cancer innovation at #GU24: https://bit.ly/49aqGoU #MyCompany
-
-
COTA and FDA Extend Collaboration to Advance Use of Real-World Data in Cancer Research - HIT Consultant Title: COTA and FDA Collaboration for Cancer Research #COTAandFDA Summary: COTA, a healthcare IT company, has extended its collaboration with the FDA to advance the use of real-world data in cancer research. The partnership aims to leverage real-world data to improve patient outcomes and inform regulatory decision-making. #RealWorldData #CancerResearch Key Points: 1. COTA's collaboration with the FDA focuses on utilizing real-world data to enhance cancer research. 2. The partnership aims to improve patient outcomes and provide valuable insights for regulatory decision-making. 3. By leveraging real-world data, researchers can gain a better understanding of cancer treatment effectiveness and patient outcomes. 4. The collaboration between COTA and the FDA highlights the importance of utilizing ai.mediformatica.com #cota #research #collaboration #data #cancer #oncology #realworlddata #cancerresearch #administration #analytics #cancertreatment #foodanddrugadministration #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/4bLTPrE)
COTA and FDA Extend Collaboration to Advance Use of Real-World Data in Cancer Research
hitconsultant.net
-
This week is the American Society of Clinical Oncology (ASCO)’s Annual Meeting in Chicago, focused on Dr. Lynn Schuchter’s Presidential theme, The Art and Science of Cancer Care: From Comfort to Cure. Lindee Goh, Tapestry’s Managing Director and healthcare practice leader, is excited to attend ASCO this year to learn about the latest developments in cancer research and care delivery. Tapestry has been involved in the oncology space for more than 15 years. Our team recognizes that today, stakeholders are grappling with a range of issues relating to advancing high-quality cancer care, including: · Navigating the ongoing exploration of value-based payment approaches in oncology, as exemplified by the Center for Medicare and Medicaid Innovation’s Enhancing Oncology Model and Tapestry's oncology alternative payment models advisory council · Accelerating precision-based approaches for cancer diagnosis and treatment, including through the use of high-quality molecular diagnostic assays to inform treatment selection, the complexities of which our team has explored through the Diagnostic Quality Assurance Pilot · Working within the changing US drug treatment landscape, which will only become more complex as drug researchers and developers navigate the implications of the Inflation Reduction Act for drug R&D, including in oncology Please learn more about our work on some of these issues: Oncology and value based care: https://lnkd.in/djxJyaSd Molecular diagnostic quality: https://lnkd.in/giFP_-Vf #ASCO #ASCO24 #cancer #valuebasedcare #innovation
-
